Profund Advisors’s Arcus Biosciences RCUS Stock Holding History

Profund Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.17M	Buy	54,163 +14,524	+37%	+$314K	0.04%	310
2025 Q4	$945K	Buy	39,639 +22,048	+125%	+$450K	0.03%	368
2025 Q3	$239K	Sell	17,591 -5,479	-24%	-$57K	0.01%	877
2025 Q2	$188K	Sell	23,070 -2,088	-8%	-$17.8K	0.01%	920
2025 Q1	$197K	Buy	25,158 +8,037	+47%	+$93.2K	0.01%	909
2024 Q4	$255K	Sell	17,121 -1,599	-9%	-$26.1K	0.01%	861
2024 Q3	$286K	Sell	18,720 -1,017	-5%	-$16K	0.01%	829
2024 Q2	$301K	Sell	19,737 -34,693	-64%	-$560K	0.01%	721
2024 Q1	$1.03M	Buy	54,430 +11,265	+26%	+$195K	0.04%	354
2023 Q4	$824K	Sell	43,165 -7,906	-15%	-$126K	0.04%	368
2023 Q3	$917K	Sell	51,071 -5,325	-9%	-$107K	0.05%	306
2023 Q2	$1.15M	Sell	56,396 -21,376	-27%	-$407K	0.06%	288
2023 Q1	$1.42M	Buy	+77,772	New	+$1.49M	0.09%	196

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Profund Advisors's RCUS Position: Q1 2026 in Review

Profund Advisors increased its Arcus Biosciences (RCUS) stake by 37% in Q1 2026, buying an estimated $314K and bringing the position to 54,163 shares worth $1.17M. The position accounts for 0.04% of the portfolio, ranked #310.

Profund Advisors first reported a position in RCUS in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.42M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

Profund Advisors held 54,163 shares of Arcus Biosciences worth $1.17M as of Q1 2026.
Profund Advisors bought 14,524 Arcus Biosciences shares in Q1 2026, an estimated $314K.
Arcus Biosciences made up 0.04% of Profund Advisors's portfolio in Q1 2026, its #310 holding.
Profund Advisors first reported a position in Arcus Biosciences in Q1 2023 and has held it in 13 quarters since.
Profund Advisors's Arcus Biosciences position peaked at $1.42M in Q1 2023.
210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.